These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [A study of safety of cefmetazole (CS-1170) in pregnant women during the perinatal stage (author's transl)].
    Journal: Jpn J Antibiot; 1981 Jun; 34(6):907-14. PubMed ID: 6945451.
    Abstract:
    Cefmetazole has a high safety rating when used in perinatal stage chemotherapy and thus it is a very useful antibiotic. However, cefmetazole is not an antibiotic to be administered primarily as a preventive. It should be used mainly in treating other agents resistant Gram-negative bacilli infections. In doing so, cefmetazole will become highly useful. 2. The safe dose of cefmetazole (CMZ) to the mother in the perinatal period is 1 approximately equal to 2 g/day. The administration of 4 g/day in a severe case is not contraindicated. 2. The fetus showed no signs of distress or side effects from cefmetazole (CMZ) crossing the mother's placental barrier. The transition of cefmetazole (CMZ) into the mother's milk is insignificant quantitatively but remains unknown qualitatively.
    [Abstract] [Full Text] [Related] [New Search]